Brexpiprazole
6 NDCs across 1 manufacturer|0 Generic,6 Brand
Brexpiprazole is used to treat major depressive disorder and schizophrenia, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jul 10, 2015, and the first generic was approved Aug 11, 2022. FDA's Orange Book lists 12 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $861 million on Brexpiprazole across 598,000 claims for 95,000 beneficiaries.
Brexpiprazole is available as 6 NDCs from 1 manufacturer (0 generic, 6 brand), with NADAC prices from $49.47 to $49.56 per EA — a 0% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
6
0G / 6B
Manufacturers
1
competing in market
Price Spread
$49.47 – $49.56
per EA
7d Activity
avg -0.0% WoW · of 6 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Otsuka America Pharmaceutical Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Atypical Antipsychotic class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing BREXPIPRAZOLE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
REXULTI 1 MG TABLET | $49.5597 per EA | -0.03% |
REXULTI 2 MG TABLET | $49.5252 per EA | -0.02% |
REXULTI 3 MG TABLET | $49.5091 per EA | -0.04% |
REXULTI 0.25 MG TABLET | $49.4971 per EA | -0.02% |
REXULTI 0.5 MG TABLET | $49.4862 per EA | -0.04% |
REXULTI 4 MG TABLET | $49.4674 per EA | -0.07% |
Frequently Asked Questions
What is Brexpiprazole used to treat?
Brexpiprazole is used to treat major depressive disorder and schizophrenia, per the National Library of Medicine's MED-RT classification.
When did Brexpiprazole become available as a generic?
FDA approved the first generic Brexpiprazole (ANDA) on Aug 11, 2022. The Orange Book currently lists 12 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Brexpiprazole?
In 2024, Medicare Part D spent $861 million on Brexpiprazole across 598,000 claims for 95,000 beneficiaries.
How many Brexpiprazole products are on the market?
The Brexpiprazole drug market contains 6 NDCs from 1 manufacturer — 0 generic and 6 brand products.
What is the price range for Brexpiprazole?
NADAC reference prices for Brexpiprazole range from $49.4674 to $49.5597 per EA — a 0% difference between cheapest and most expensive.
Which manufacturers make Brexpiprazole?
1 manufacturer lists Brexpiprazole in NADAC. Ranked by number of NDCs, the largest are Otsuka America Pharmaceutical Inc. (6).
How has the price of Brexpiprazole changed recently?
Over the past 7 days, 0 Brexpiprazole NDCs rose and 6 fell, with a market-wide average change of -0.0%.